Soluble HIV-1 envelope glycoprotein trimers

Patent metadata

Field	Value
Publication number	US-10058604-B2
Application number	US-201414508369-A
Country	US
Kind code	B2
Filing date	Oct 7, 2014
Priority date	Oct 7, 2013
Publication date	Aug 28, 2018
Grant date	Aug 28, 2018

Abstract

The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

First claim

What is claimed is:

1. An engineered or non-naturally occurring JRFL SOSIP trimer that mimics the native HIV spike conformation and is stable at 55° C. to 63° C., wherein the trimer comprises
(a) the amino acid sequence of SEQ ID NO: 8, or
(b) the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 9 further comprising cysteine mutations V135C, N136C, A137C, T138C, F159C, N160C, I161C, T162C, T163C, S164C, I165C, S306C, 1307C, H308C, R315C, A316C, F317C, Y318C, T319C, or T320C thereof, or
(c) the amino acid sequence of SEQ ID NO: 10 or
(d) the amino acid sequence of SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NO: 13, or wherein VQSEKS in any of the three sequences is replaced with SEQ ID NO: 1.

2. The trimer of claim 1 , wherein the JRFL SOSIP trimer is truncated at residue 663 when aligned with SEQ ID NO: 14 based on BG505 numbering system and/or the JRFL SOSIP is stabilized by disulfide linkages, preferably by a first disulfide between residues 201 and 433 and/or a second disulfide between residues 163 and 309.

3. An engineered or non-naturally occurring 16055 SOSIP trimer that mimics the native HIV spike conformation and is stable at 55° C. to 63° C., wherein the 16055 SOSIP trimer is truncated at residue 663 when aligned with SEQ ID NO: 14 based on BG505 numbering system.

4. An engineered or non-naturally occurring native flexible linker (NFL) gp140 trimer comprising the amino acid sequence of SEQ ID NO: 2, wherein a linker covalently joins the C terminus of gp120 with the N terminus of gp41.

5. The trimer of claim 4 , wherein the linker comprises SEQ ID NO: 2, SEQ ID NO: 6, or SEQ ID NO: 7, wherein SEQ ID NO: 3 residues are deleted from the C-terminus of gp 120 and wherein the C terminus of gp41 comprises a His tag.

6. The trimer of claim 4 , wherein the trimer comprises
(a) the amino acid sequence of SEQ ID NO: 14, or
(b) the amino acid sequence of SEQ ID NO: 15, or
(c) the amino acid sequence of SEQ ID NO: 16, or
(d) the amino acid sequence of SEQ ID NO: 17, or
(e) the amino acid sequence of SEQ ID NO: 18.

7. The trimer of claim 4 , wherein the trimer is truncated following residue 664 when aligned with SEQ ID NO: 14 based on BG505 numbering system.

8. The trimer of claim 4 , wherein the trimer comprises a His tag.

9. The trimer of claim 4 , wherein the trimer is mutated.

10. The trimer of claim 9 , wherein the mutation is a proline substitution.

11. The trimer of claim 9 , wherein the mutation is selected from the group consisting of S649D, S649E, L555P, L556P, A558P and I559P, wherein the residue numbers are based on BG505 numbering system when aligned with SEQ ID NO: 14, preferably wherein the mutation is I559P.

12. The trimer of claim 9 , wherein the mutation is a double mutant containing combinations of 649D or E with the other HR1 P mutations.

13. The trimer of claim 9 wherein the mutation is selected from the group consisting of E47D, K49E, V65K, E106T, I165L, E429R, R432Q, wherein the residue numbers are based on BG505 numbering system when aligned with SEQ ID NO: 14, or a subset thereof.

14. The trimer of claim 10 , wherein the mutation is selected from the group consisting of L555P, Q652P, Q653P, L565P and L566P or any combination thereof, wherein the residues based on 16055 SEQ ID NO: 17 numbering.

15. The trimer of claim 10 , wherein the mutation is a double mutant selected from the group consisting of A558P-S649D, A558P-S649E and I559P-S649E, wherein the residues based on 16055 SEQ ID NO: 17 numbering.

16. The trimer of claim 4 wherein the trimer is a BG505 trimer or is a trimer homologous to BG505 from HIV subtypes A, B or C, wherein the trimer comprises any one of the sequences of SEQ ID NOS 21-24 or SEQ ID NOS 26-29 or a sequence having 95% identity thereof.

17. The trimer of claim 4 comprising a free cysteine.

Assignees

• Int Aids Vaccine Initiative
• Scripps Research Inst

Inventors

• Wyatt Richard
• Ward Andrew
• Tran Karen
• Kumar Shailendra
• Ingale Jidnyasa
• Guenaga Javier
• Feng Yu
• Dubrovskaya Viktoriya
• De Val Alda Natalia

Classifications

• C12N2740/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• C12N2740/16122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C07K14/005

  from viruses · CPC title

• C07K14/162

  env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site · CPC title